What is unique regarding this technology is that it uses antibodies to recognize tumor tissue. In order to eliminate the cancer cells, these antibodies – via the link with Syntarga – bind with the chemotherapeutic material that will eventually also be developed by the company. Through the release of substances by the cancer tumor, the separate parts come together in combination with exactly the right chemical balance that is effective in fighting cancer. There are few, if any, side effects. The combination of antibodies and cancer drugs is called “Antibody Drug Conjugate,” or ADC.

Investing in a health future

An investment in Syntarga by PPM Oost has made this new technology possible.

www. syntarga .com